

Highlights of This Issue 1503

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 1505** CCR 20th Anniversary Commentary: In Search of Cetuximab's First Indication—Combination Therapy with Irinotecan in Colorectal Cancer
Daniel J. Hicklin


CCR Translations

- 1508** Pancreatic Cancer–Associated Diabetes Is an "Exosomopathy"
Murray Korc
See related article, p. 1722
- 1511** Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy
Neelima Vidula and Hope S. Rugo
See related article, p. 1688

CCR Perspectives in Drug Approval

- 1514** Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Roy S. Herbst, David R. Gandara, Fred R. Hirsch, Mary W. Redman, Michael LeBlanc, Philip C. Mack, Lawrence H. Schwartz, Everett Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Dana Sparks, Yang Zhou, Crystal Miwa, Vincent A. Miller, Roman Yelensky, Yali Li, Jeff D. Allen, Ellen V. Sigal, David Wholley, Caroline C. Sigman, Gideon M. Blumenthal, Shakun Malik, Gary J. Kelloff, Jeffrey S. Abrams, Charles D. Blanke, and Vassiliki A. Papadimitrakopoulou
- 1525** FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
Barry W. Miller, Donna Przepioraka, R. Angelo de Claro, Kyung Lee, Lei Nie, Natalie Simpson, Ramadevi Gudi, Haleh Saber, Stacy Shord, Julie Bullock, Dhanaanjay Marathe, Nitin Mehrotra, Li Shan Hsieh, Debasis Ghosh, Janice Brown, Robert C. Kane, Robert Justice, Edvardas Kaminskas, Ann T. Farrell, and Richard Pazdur
See related article, p. 1537

Statistics in Clinical Cancer Research

- 1530** Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time
 Stefanie Hieke, Martina Kleber, Christine König, Monika Engelhardt, and Martin Schumacher

CCR Drug Updates

- 1537** Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Qingshan Yang, Prexy Modi, Terry Newcomb, Christophe Quéva, and Varsha Gandhi
See related article, p. 1525

Molecular Pathways

- 1543** Molecular Pathways: Aspirin and Wnt Signaling—A Molecularly Targeted Approach to Cancer Prevention and Treatment
Manish K. Gala and Andrew T. Chan

Review

- 1549** Nonviral Oncogenic Antigens and the Inflammatory Signals Driving Early Cancer Development as Targets for Cancer Immunoprevention
Nina J. Chu, Todd D. Armstrong, and Elizabeth M. Jaffee

CANCER THERAPY: CLINICAL

- 1558** A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Maryam Fouladi, John P. Perentesis, Lars M. Wagner, Alexander A. Vinks, Joel M. Reid, Charlotte Ahern, George Thomas, Carol A. Mercer, Darcy A. Krueger, Peter J. Houghton, L. Austin Doyle, Helen Chen, Brenda Weigel, and Susan M. Blaney
- 1566** A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Thomas J. Galloway, Lori J. Wirth, Alexander D. Colevas, Jill Gilbert, Julie E. Bauman, Nabil F. Saba, David Raben, Raneeh Mehra, Anna W. Ma, Ruzanna Atoyan, Jing Wang, Barbara Burtneis, and Antonio Jimeno

Table of Contents

1574 Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel A. Villalona-Calero, Robert J. Morgan Jr, Peter M. Szabo, Ahrim Youn, Alice P. Chen, Jiuping Ji, Deborah E. Allen, Chih-Jian Lih, Michele G. Mehaffey, William D. Walsh, Paul M. McGregor III, Seth M. Steinberg, P. Mickey Williams, Robert J. Kinders, Barbara A. Conley, Richard M. Simon, and James H. Doroshow

PERSONALIZED MEDICINE AND IMAGING

1583 Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation

Pierre Bohanes, Cathryn J. Rankin, Charles D. Blanke, Thomas Winder, Cornelia M. Ulrich, Stephen R. Smalley, Tyvin A. Rich, James A. Martensen, Al B. Benson III, Robert J. Mayer, Christine M. Cripps, Kathleen Danenberg, Karen W. Makar, Wu Zhang, Jacqueline K. Benedetti, and Heinz-Josef Lenz

1591 *KEAP1* Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes

Jaana M. Hartikainen, Maria Tengström, Robert Winqvist, Arja Jukkola-Vuorinen, Katri Pylkäs, Veli-Matti Kosma, Ylermi Soini, and Arto Mannermaa

1602 Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Fuman Qiu, Lei Yang, Xiaoxuan Ling, Rongrong Yang, Xiaorong Yang, Lisha Zhang, Wenxiang Fang, Chenli Xie, Dongsheng Huang, Yifeng Zhou, and Jiachun Lu

1614 *DNMT3A* Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Alison R. Sehgal, Phyllis A. Gimotty, Jianhua Zhao, Jing-Mei Hsu, Robert Daber, Jennifer D. Morrisette, Selina Luger, Alison W. Loren, and Martin Carroll

1621 Improvements in Radiographic Progression-Free Survival Stratified by *ERG* Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Gerhardt Attard, Johann S. de Bono, Christopher J. Logothetis, Karim Fizazi, Som D. Mukherjee, Anthony M. Joshua, Dirk Schrijvers, Alfons J.M. van den Eertwegh, Weimin Li, Arturo Molina, Thomas W. Griffin, Thian Kheoh, Deborah S. Ricci, Kathy Zelinsky, Dana E. Rathkopf, Howard I. Scher, and Charles J. Ryan

CANCER THERAPY: PRECLINICAL

1628 The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurizio Ponzoni, Afua Adjeiwaa Mensah, Anastasios Stathis, Georg Stussi, Maria Eugenia Riveiro, Patrice Herait, Giorgio Inghirami, Esteban Cvitkovic, Emanuele Zucca, and Francesco Bertoni

1639 The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Li Liu, Patrick A. Mayes, Stephen Eastman, Hong Shi, Sapna Yadavilli, Tianqian Zhang, Jingsong Yang, Laura Seestaller-Wehr, Shu-Yun Zhang, Chris Hopson, Lyuben Tsvetkov, Junping Jing, Shu Zhang, James Smothers, and Axel Hoos

1652 BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Tao Wang, Min Xiao, Yingbin Ge, Clemens Krepler, Eric Belser, Alfonso Lopez-Coral, Xiaowei Xu, Gao Zhang, Rikka Azuma, Qin Liu, Rui Liu, Ling Li, Ravi K. Amaravadi, Wei Xu, Giorgos Karakousis, Tara C. Gangadhar, Lynn M. Schuchter, Melissa Lieu, Sanika Khare, Molly B. Halloran, Meenhard Herlyn, and Russel E. Kaufman

1665 A Novel *CDC25B* Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models

Helga L. Weber, Manuel Gidekel, Santiago Werbach, Edgardo Salvatierra, Cecilia Rotondaro, Leonardo Sganga, Gabriela Acosta Haab, David T. Curiel, Eduardo G. Cafferata, and Osvaldo L. Podhajcer

1675 Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

Yoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi, Fan Zhang, Alexander W. Wyatt, Nader Al Nakouzi, Fan Mo, Tianyuan Zhou, Youngsoo Kim, Brett P. Monia, A. Robert MacLeod, Ladan Fazli, Yuzhuo Wang, Colin C. Collins, Amina Zoubeydi, and Martin Gleave

Table of Contents

BIOLOGY OF HUMAN TUMORS

- 1688** Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein, Anna Tsimelzon, Graham M. Poage, Kyle R. Covington, Alejandro Contreras, Suzanne A.W. Fuqua, Michelle I. Savage, C. Kent Osborne, Susan G. Hilsenbeck, Jenny C. Chang, Gordon B. Mills, Ching C. Lau, and Powel H. Brown
See related commentary, p. 1511
- 1699** Global Promoter Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes in Natural Killer Cell Lymphoma
Can Küçük, Xiaozhou Hu, Bei Jiang, David Klinkebiel, Huimin Geng, Qiang Gong, Alyssa Bouska, Javeed Iqbal, Philippe Gaulard, Timothy W. McKeithan, and Wing C. Chan
- 1712** Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma
Sabrina Fichtner, Dirk Hose, Melanie Engelhardt, Tobias Meißner, Brigitte Neuber, Fatime Krasniqi, Marc Raab, Stefan Schönland, Anthony D. Ho, Hartmut Goldschmidt, and Michael Hundemer
- 1722** Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β -cell Dysfunction
Naureen Javeed, Gunisha Sagar, Shamit K. Dutta, Thomas C. Smyrk, Julie S. Lau, Santanu Bhattacharya, Mark Truty, Gloria M. Petersen, Randal J. Kaufman, Suresh T. Chari, and Debabrata Mukhopadhyay
See related commentary, p. 1508
- 1734** Habitual Myofibrillar Protein Synthesis Is Normal in Patients with Upper GI Cancer Cachexia
Alisdair J. MacDonald, Neil Johns, Nathan Stephens, Carolyn Greig, James A. Ross, Alexandra C. Small, Holger Husi, Kenneth C.H. Fearon, and Tom Preston

- 1741** Loss of *SOD3* (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma
Brianna R. O'Leary, Melissa A. Fath, Andrew M. Bellizzi, Jennifer E. Hrabe, Anna M. Button, Bryan G. Allen, Adam J. Case, Sean Altekruze, Brett A. Wagner, Garry R. Buettner, Charles F. Lynch, Brenda Y. Hernandez, Wendy Cozen, Robert A. Beardsley, Jeffery Keene, Michael D. Henry, Frederick E. Domann, Douglas R. Spitz, and James J. Mezhir
- 1752** *BATF2* Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs
Zebing Liu, Ping Wei, Yu Yang, Wenli Cui, Bing Cao, Cong Tan, Baohua Yu, Rui Bi, Kaiqin Xia, Weixiang Chen, Yiqin Wang, Youyuan Zhang, Xiang Du, and Xiaoyan Zhou
- 1764** Cross-Species Antibody Microarray Interrogation Identifies a 3-Protein Panel of Plasma Biomarkers for Early Diagnosis of Pancreas Cancer
Justin E. Mirus, Yuzheng Zhang, Christopher I. Li, Anna E. Lokshin, Ross L. Prentice, Sunil R. Hingorani, and Paul D. Lampe

CORRECTIONS

- 1772** Correction: Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
- 1773** Correction: TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma *In Vivo*
- 1774** Correction: Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma



 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The image shows the 4 stable subtypes of triple-negative breast cancer defined by gene signature. These subtypes (luminal androgen receptor, mesenchymal, basal-like immunosuppressed, and basal-like immune-activated) are characterized by the expression of distinct molecular profiles that have disparate prognoses. For details, see the article by Burstein and colleagues on page 1688 of this issue.



Clinical Cancer Research

21 (7)

Clin Cancer Res 2015;21:1503-1775.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.